Tinlarebant

Phase 3Small molecule

BBelite Bio, Inc

Tinlarebant is one of 56 small molecule programs targeting Geographic Atrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geographic AtrophyActive, not recruiting

Efficacy and SafetyActive, not recruiting

Geographic AtrophyPhase 3

Active, not recruiting

Efficacy and SafetyPhase 3

Active, not recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Gilotrif

Boehringer Ingelheim

Phase 3

3 2

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

1 3

Oxycontin

PPurdue Pharma LP

Phase 3

1 4

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

4 5

Avalglucosidase Alfa

Sanofi

Phase 3

1 6

PLB1004

AAvistone Biotechnology Co., Ltd.

Phase 3

1 7

Tpoxx

SSIGA Technologies

Phase 3

1 8

Hemay005

GGanzhou Hemay Pharmaceutical Co., Ltd

Phase 3

2 9

Rhtpo

SShandong University

Phase 3

1 10

KN057

SSuzhou Alphamab Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Geographic Atrophy

NCT05949593

Q1 2028

Phase 2/3Active, not recruiting

Efficacy and Safety

NCT06388083

Clinical

Trials by Indication[1]

Geographic Atrophy1 trial

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Active, not recruiting·BBelite Bio, Inc·Phase 3·NCT05949593·429 enrolled

Stargardt Disease1 trial

This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease

Completed·RRBP4 Pty Ltd·Phase 1/2·NCT05266014·13 enrolled

Tics1 trial

Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85

Completed·RRBP4 Pty Ltd·Phase 1·NCT05667688·15 enrolled

Efficacy and Safety1 trial

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

Active, not recruiting·BBelite Bio, Inc·Phase 2/3·NCT06388083·60 enrolled

Stargardt Disease 11 trial

Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects

Completed·BBelite Bio, Inc·Phase 3·NCT05244304·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Tinlarebant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tinlarebant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tinlarebant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Belite Bio, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBelite Bio, Inc

Tinlarebant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Trials by Indication[1]

Geographic Atrophy1 trial

Stargardt Disease1 trial

Tics1 trial

Efficacy and Safety1 trial

Stargardt Disease 11 trial

References

Drug Info

Quick Facts

Related News